Funding for this research was provided by:
Lund University Medical Faculty Foundation (Lund University Medical Faculty Foundation)
Crafoordska Stiftelsen (Crafoordska Stiftelsen)
Greta och Johan Kocks stiftelser (Greta och Johan Kocks stiftelser)
Stiftelsen Konung Gustaf V:s 80-årsfond (Stiftelsen Konung Gustaf V:s 80-årsfond)
Magnus Bergvalls Stiftelse (Magnus Bergvalls Stiftelse)
Alfred Österlunds Stiftelse (Alfred Österlunds Stiftelse)
Received: 4 May 2022
Accepted: 1 December 2022
First Online: 9 December 2022
: The study obtained ethics approval by the Lund Regional Ethics Board diary numbers 2012/254 & 2012/677 (on January 1st 2019 the six Swedish regional boards were combined into one authority, the Swedish Ethical Review Authority). The study was conducted in compliance with the 1964 Helsinki Declaration and its later amendments. Informed consent was obtained from all individual participants included in the study.
: Not applicable.
: OH has acquired research support (for the institution) from AVID Radiopharmaceuticals, Biogen, Eli Lilly, Eisai, GE Healthcare, Pfizer, and Roche. In the past 2 years, he has received consultancy/speaker fees from Roche, Genentech, Siemens, Biogen, Alzpath, and Cerveau. AJ has received consultancy fees from GlaxoSmithKline and Astra Zeneca. The other authors have no competing interests to declare.